Skip to main content

Day: September 26, 2023

Cynthia Romano and Chris Creger Join FTI Consulting’s Turnaround & Restructuring Practice

WASHINGTON, Sept. 26, 2023 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointments of Cynthia Romano and Chris Creger as Senior Managing Directors in the Turnaround & Restructuring practice within the firm’s Corporate Finance & Restructuring segment. “Cynthia and Chris have a track record of helping clients get back to the basics of growing revenue, cutting unnecessary expenses and improving operations,” said Michael Eisenband, Global Co-Leader of the Corporate Finance & Restructuring segment at FTI Consulting. “Their restructuring leadership and performance improvement expertise combined with our deep bench of industry experts will help our clients transform their bottom line to maximize value for owners, investors and other stakeholders.” Ms. Romano, who splits her time between New...

Continue reading

Fang Holdings Announces Formation of Special Committee

BEIJING, Sept. 26, 2023 (GLOBE NEWSWIRE) — Fang Holdings Limited (OTC: SFUNY) (“Fang” or the “Company”), a leading real estate Internet portal in China, today announced that its board of directors (the “Board”) has formed a special committee (the “Special Committee”) consisting of three independent directors, Mr. Huyue Zhang, Mr. Shaohua Zhang and Mr. Changming Yan, to evaluate and consider the previously announced preliminary non-binding acquisition proposal letter dated September 4, 2023 (the “Proposal”) from Mr. Jiangong Dai (“Mr. Dai” or the “Proposing Buyer”) to acquire all of the outstanding shares of the Company not currently owned by the Proposing Buyer, or any potential alternative transactions. The Board cautions the Company’s shareholders and others considering trading the Company’s securities that no decisions have...

Continue reading

CTO Realty Growth Announces Third Quarter 2023 Earnings Release and Conference Call Information

WINTER PARK, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) — CTO Realty Growth (NYSE: CTO) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2023 after the market closes on Thursday, October 26, 2023. A conference call to discuss its financial and operating results is scheduled for Friday, October 27, 2023 at 9:00 AM ET. A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.ctoreit.com or at the link provided in the event details below. To access the call by phone, please go to the registration link provided in the event details below and you will be provided with dial-in details. Event Details:Webcast: https://edge.media-server.com/mmc/p/zzoarkysRegistration: https://register.vevent.com/register/BIc2862b1fbbca4c92b7d5c569a5f682e5   We...

Continue reading

Triterras Announces the Addition of Two New Hires to Serve a Growing Pipeline of Funding Opportunities

Marina Golubeva and Ali Rakib join the company as the Digital Trade and Supply Chain Finance provider expands its lending portfolio in both emerging and developed markets DUBAI, United Arab Emirates, Sept. 26, 2023 (GLOBE NEWSWIRE) — Triterras, Inc. (“Triterras” or the “Company”) a leading fintech company focused on trade and trade finance, announces the hiring of two new members to the Distribution team. Marina Golubeva and Ali Rakib will engage with institutional investors who are interested in deploying capital for cross-border trade finance opportunities. Marina and Ali will report to Marina Naganes, Head of Distribution & Sales Strategy. Ms. Golubeva joins the Distribution team as Vice President of Business Development. Prior to Triterras, Ms. Golubeva worked in trade and structured finance for BTA Bank, Nordea Bank and...

Continue reading

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity, will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th Annual Meeting of the European Association for the Study of Diabetes in Hamburg, Germany. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH). Details for the oral presentation are as follows:Title: Phase 2, Randomized, Placebo-controlled Trial of pemvidutide,...

Continue reading

Deep-South Closed the Oversubscribed Private Placement Totaling $2,068,729

Not for Distribution to United States Newswire Services or for Dissemination in the United States VANCOUVER, British Columbia, Sept. 26, 2023 (GLOBE NEWSWIRE) — Deep-South Resources Inc. (“Deep-South” or the Company) (TSX-V: DSM) announces that the Company closed the second tranche of its oversubscribed non-brokered private placement (“Private Placement”) for an amount totaling $1,803,282. The first tranche closed September 6, 2023 for an amount of $265,447. The two tranches together total $2,068,729. In aggregate, the two tranches of the Private Placement comprise 31,826,596 units (the “Units”) of Deep-South, at a subscription price of $0.065 per Unit. Each Unit consists of one (1) common share and one half (1/2) of one common share purchase warrant (“Warrant”). Each full Warrant will entitle the holder thereof to...

Continue reading

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Efficacy ChartEfficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression • No apparent differences in the safety and tolerability profile of SPL026 (DMT) following administration to participants in the SSRI and non-SSRI patient cohorts LONDON, Sept. 26, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive safety,...

Continue reading

Ovid Therapeutics to Host Investor Event – R&D Day on Monday, October 2, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm – 2:30 pm and will be webcast simultaneously. Ovid management will provide updates on Ovid’s scientific strategy and anticipated clinical development plans. Additionally, the Company’s research and development leadership will review new data characterizing how the unique mechanisms of action in its pipeline address the underlying causes of neuronal hyperexcitability and may hold broader...

Continue reading

Signature of a Three-Party MOU on the Commercialization of Novacium’s Hydrogen Production System

MONTREAL, Sept. 26, 2023 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ) (OTCQB: HPQFF) (FRA: O08), a technology company specializing in green engineering of silica and silicon-based materials is pleased to announce that HPQ and its Lyon-based affiliate, Novacium SAS, have signed a three-party memorandum of understanding (MOU) with LN INNOV’ SAS of Toulouse, France. LN INNOV’ is a French networking company with a strong presence in various sectors, including Defense. Leveraging its extensive network, LN INNOV’ aims to streamline access to innovative energy projects like the one presented by Novacium and HPQ. Their goal is to connect key industry stakeholders and expedite the transition of innovative projects from the research and development phase to commercialization. “France has set the goal...

Continue reading

Alpine Income Property Trust Announces Third Quarter 2023 Earnings Release and Conference Call Information

WINTER PARK, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced today that it will report its financial and operating results for the third quarter of 2023 after the market closes on Thursday, October 19, 2023. A conference call to discuss its financial and operating results is scheduled for Friday, October 20, 2023 at 9:00 AM ET. A live webcast of the call will be available on the Investor Relations page of the Company’s website at www.alpinereit.com or at the link provided in the event details below. To access the call by phone, please go to the link provided in the event details below and you will be provided with dial-in details.Event Details:  Webcast: https://edge.media-server.com/mmc/p/fg68mtir  Dial-In: https://register.vevent.com/register/BI7fdbafb88c2e4305bc44b67274dc0cca     We...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.